famotidine has been researched along with Heart Defects, Congenital in 1 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behrens, R | 1 |
| Hofbeck, M | 1 |
| Singer, H | 1 |
| Scharf, J | 1 |
| Rupprecht, T | 1 |
1 trial available for famotidine and Heart Defects, Congenital
| Article | Year |
|---|---|
Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Famotidine; Female; Heart Defects, Congenit | 1994 |